000303473 001__ 303473
000303473 005__ 20250904143121.0
000303473 0247_ $$2doi$$a10.1128/spectrum.00071-25
000303473 0247_ $$2pmid$$apmid:40748074
000303473 037__ $$aDKFZ-2025-01670
000303473 041__ $$aEnglish
000303473 082__ $$a570
000303473 1001_ $$00009-0002-8268-7485$$aRinne, Sanni$$b0
000303473 245__ $$aEpstein-Barr virus (EBV) serology and its impact on oral human papillomavirus (HPV) infection outcomes in children during early childhood.
000303473 260__ $$aBirmingham, Ala.$$bASM$$c2025
000303473 3367_ $$2DRIVER$$aarticle
000303473 3367_ $$2DataCite$$aOutput Types/Journal article
000303473 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756989048_27122
000303473 3367_ $$2BibTeX$$aARTICLE
000303473 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303473 3367_ $$00$$2EndNote$$aJournal Article
000303473 500__ $$a2025 Sep 2;13(9):e0007125
000303473 520__ $$aEpstein-Barr virus (EBV) and various human papillomaviruses (HPVs) commonly infect the oral mucosa, yet the longitudinal effects of these infections and their potential coinfections remain poorly understood. This study investigated whether early EBV infection and antibody responses influence oral HPV infections in young children. We included 283 children from the Finnish Family HPV cohort study, who were followed for 3 years post-birth. Oral and blood samples were collected at six time points (1, 2, 6, 12, 24, and 36 months). HPV genotyping was performed with Luminex and EBV-IgG antibodies to Zebra, early antigen-diffuse (EA-D), EBV nuclear antigen 1, and viral capsid antigen p18 with fluorescent bead-based multiplex serology. We noticed that most children (91.4%; n = 254) experienced the vanishing of maternal EBV-IgG antibodies within 11.3 months, and by 36 months, 17% (41/238) of the children had developed their own EBV antibodies. Intriguingly, higher paternal education levels were strongly associated with lower EBV seropositivity in children at ages 2 and 3, with an odds ratio(OR) range of 0.06 to 0.16 (95% confidence interval range 0.005-0.91). Additionally, children with the highest baseline titers of EA-D antibodies had 2.5- and threefold risk for incident oral HPV infection and its clearance, respectively. Our findings suggest that EBV seropositivity at 3 years of age is relatively low in our Finnish data, and the level of paternal education was a significant protective factor against early EBV seropositivity. Moreover, the observed association between high EA-D antibody titers and oral HPV infection underscores the need for further research into the complex interactions between EBV and HPV.IMPORTANCEEpstein-Barr virus (EBV) and human papillomaviruses (HPVs) are known to cause cancers in the head and neck region, yet their interactions in young children remain largely unexplored. EBV, associated with infectious mononucleosis, and oral HPV, often asymptomatic in early childhood, target similar anatomical regions but are poorly studied together in this age group. Understanding these interactions is crucial, as the incidence of HPV-related oropharyngeal cancers has been rising over recent decades, making the natural history of oral HPV infections a critical research focus. While our study found no significant link between EBV seropositivity and oral HPV outcomes in children, evidence in adults suggests these viruses may interact in cancer development. Investigating this dynamic in early childhood could provide valuable insights into infection patterns and inform prevention strategies to reduce cancer risks later in life.
000303473 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000303473 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303473 650_7 $$2Other$$aEBV serology
000303473 650_7 $$2Other$$aEpstein-Barr virus
000303473 650_7 $$2Other$$achildren
000303473 650_7 $$2Other$$ahuman papillomavirus
000303473 650_7 $$2Other$$aoral HPV infection
000303473 7001_ $$0P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e$$aMichels, Birgitta$$b1$$udkfz
000303473 7001_ $$0P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aButt, Julia$$b2$$udkfz
000303473 7001_ $$aSyrjänen, Kari$$b3
000303473 7001_ $$aGrenman, Seija$$b4
000303473 7001_ $$0P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aWaterboer, Tim$$b5$$udkfz
000303473 7001_ $$aSyrjänen, Stina$$b6
000303473 7001_ $$00000-0002-1172-363X$$aLouvanto, Karolina$$b7
000303473 773__ $$0PERI:(DE-600)2807133-5$$a10.1128/spectrum.00071-25$$gp. e00071-25$$n9$$pe0007125$$tMicrobiology spectrum$$v13$$x2165-0497$$y2025
000303473 909CO $$ooai:inrepo02.dkfz.de:303473$$pVDB
000303473 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b48bfd64120195b64b5f11d32ce5ed5e$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000303473 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)31d7c3e829be03400641f80b821ef728$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000303473 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000303473 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000303473 9141_ $$y2025
000303473 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMICROBIOL SPECTR : 2022$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-02-02T17:55:23Z
000303473 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-02-02T17:55:23Z
000303473 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review, Anonymous peer review$$d2022-02-02T17:55:23Z
000303473 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2022-02-02T17:55:23Z
000303473 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-27
000303473 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-27
000303473 9201_ $$0I:(DE-He78)D320-20160331$$kD320$$lInfektionen und Krebs-Epidemiologie$$x0
000303473 980__ $$ajournal
000303473 980__ $$aVDB
000303473 980__ $$aI:(DE-He78)D320-20160331
000303473 980__ $$aUNRESTRICTED